US8642012 — Methods of treatment using ammonia-scavenging drugs
Method of Use · Assigned to Horizon Therapeutics LLC · Expires 2030-09-22 · 4y remaining
What this patent protects
This patent protects methods for determining and adjusting the dose of ammonia-scavenging drugs, such as Ravicti, based on patient factors like dietary protein intake and urinary nitrogen levels.
USPTO Abstract
The invention provides a method for determining a dose and schedule and making dose adjustments of PBA prodrugs used to treat nitrogen retention states, or ammonia accumulation disorders, by measuring urinary excretion of phenylacetylglutamine and/or total urinary nitrogen. The invention provides methods to select an appropriate dosage of a PBA prodrug based on the patient's dietary protein intake, or based on previous treatments administered to the patient. The methods are applicable to selecting or modifying a dosing regimen for a subject receiving an orally administered ammonia scavenging drug.
Drugs covered by this patent
- Ravicti (GLYCEROL PHENYLBUTYRATE) · Horizon Therap Us
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1383 |
— | Ravicti |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.